De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Vincerx Pharma Toekomstige groei

Future criteriumcontroles 0/6

De winst van Vincerx Pharma zal naar verwachting dalen met 21.3% per jaar, terwijl de jaarlijkse omzet naar verwachting zal groeien met 72.4% per jaar. De winst per aandeel zal naar verwachting groeien met 5% per jaar.

Belangrijke informatie

-21.3%

Groei van de winst

5.0%

Groei van de winst per aandeel

Biotechs winstgroei	28.7%
Inkomstengroei	72.4%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	15 Aug 2024

Recente toekomstige groei-updates

Recent updates

Winst- en omzetgroeiprognoses

NasdaqCM:VINC - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	1	-62	-43	N/A	1
12/31/2025	N/A	-37	-27	N/A	3
12/31/2024	N/A	-32	-12	N/A	3
6/30/2024	N/A	-28	-28	-28	N/A
3/31/2024	N/A	-38	-35	-35	N/A
12/31/2023	N/A	-40	-40	-40	N/A
9/30/2023	N/A	-47	-46	-46	N/A
6/30/2023	N/A	-54	-54	-54	N/A
3/31/2023	N/A	-61	-58	-58	N/A
12/31/2022	N/A	-63	-60	-60	N/A
9/30/2022	N/A	-58	-57	-57	N/A
6/30/2022	N/A	-66	-53	-53	N/A
3/31/2022	N/A	-49	-45	-45	N/A
12/31/2021	N/A	-39	-39	-33	N/A
9/30/2021	N/A	-49	-29	-24	N/A
6/30/2021	N/A	-25	-19	-14	N/A
3/31/2021	N/A	-23	-11	-6	N/A
12/31/2020	N/A	-17	-2	-2	N/A
9/30/2020	N/A	0	0	0	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat VINC de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat VINC de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat VINC de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: Er wordt verwacht dat VINC volgend jaar geen omzet zal hebben.

Hoge groei-inkomsten: Er wordt verwacht dat VINC volgend jaar geen omzet zal hebben.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van VINC naar verwachting over 3 jaar hoog zal zijn

Vincerx Pharma Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target increased by 35% to US$9.00

Price target decreased to US$8.40

Price target decreased to US$12.60

Price target decreased to US$21.33

Price target decreased to US$23.86

Price target decreased to US$26.57

Recent updates

Here's Why Vincerx Pharma (NASDAQ:VINC) Must Use Its Cash Wisely

New major risk - Financial position

Insufficient new directors

New major risk - Negative shareholders equity

New minor risk - Shareholder dilution

Vincerx Pharma, Inc. has completed a Follow-on Equity Offering.

Vincerx Pharma, Inc. has filed a Follow-on Equity Offering.

Vincerx Pharma, Inc., Annual General Meeting, May 23, 2024

New minor risk - Market cap size

Vincerx Pharma, Inc. Presents Positive Preliminary Phase 1 Data for Vip236 and Updates on Pipeline Progress At the American Association for Cancer Research (Aacr) Annual Meeting 2024

Vincerx Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Vincerx Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Price target increased by 35% to US$9.00

New major risk - Share price stability

Vincerx Pharma, Inc. Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma

New major risk - Financial position

New major risk - Revenue and earnings growth

Vincerx Pharma Receives Non-Compliance Notice from the Nasdaq Stock Market

Vincerx Pharma Receives Non-Compliance Notice from the Nasdaq Stock Market

Vincerx Pharma, Inc. Announces FDA Clearance of IND for VIP943

Can Vincerx Pharma (NASDAQ:VINC) Afford To Invest In Growth?

New major risk - Financial position

Can Vincerx Pharma (NASDAQ:VINC) Afford To Invest In Growth?

Vincerx Pharma, Inc. Announces Resignation of Board of Directors

Vincerx Pharma Announces Fda Safe to Proceed Letter for Investigational New Drug (Ind) Application for Its <Alpha>V<Beta>3 Small Molecule-Drug Conjugate (Smdc) Vip236

Price target decreased to US$8.40

Vincerx Pharma, Inc. Presents Preclinical Data on VIP943 in Acute Myeloid Leukemia Models at the 64th American Society of Hematology Annual Meeting 2022

Price target decreased to US$12.60

High number of new and inexperienced directors

Can Vincerx Pharma (NASDAQ:VINC) Afford To Invest In Growth?

Founder recently bought US$56k worth of stock

Vincerx Pharma, Inc.(NasdaqCM:VINC) dropped from Russell 2000 Growth Index

Is Vincerx Pharma (NASDAQ:VINC) In A Good Position To Invest In Growth?

Vincerx Pharma Presents Preclinical and Clinical Data on PTEFb/CDK9 Inhibitor VIP152 in Lymphoma at the European Hematology Association 2022 Congress

Vincerx Pharma, Inc. Announces Departure of Hermes Garban as Chief Medical Officer, Effective on or Before August 6, 2022

Vincerx Pharma, Inc. Provides Clinical Updates

Price target decreased to US$21.33

High number of new and inexperienced directors

Vincerx, Inc., Annual General Meeting, May 26, 2022

Price target decreased to US$23.86

Price target decreased to US$26.57

High number of new and inexperienced directors

Founder recently bought US$65k worth of stock

Vincerx Pharma, Inc. Announces First Patient Dosed in Phase 1 Dose-Escalation Study of VIP152 in Relapsed or Refractory Chronic Lymphocytic Leukemia or Richter Syndrome

Vincerx Pharma Presents Data on PTEFb/CDK9 Inhibitor VIP152 in DLBCL and CLL at the 63rd American Society of Hematology Annual Meeting

Vincerx Pharma Receives Orphan Drug Designation from European Commission for VIP152 for the Treatment of Diffuse Large B-Cell Lymphoma

Independent Director recently bought US$126k worth of stock

Vincerx Pharma Presents Clinical Data on VIP512, its PTEFb/CDK9 Inhibitor, in Patients with Double-Hit Lymphoma at ASCO 2021

Vincerx Pharma Announces First Patient Dosed in Phase 1b Study of VIP152 in MYC-Driven Relapsed or Refractory Aggressive Lymphomas and Advanced Solid Tumors

Vincerx Pharma doses first patient in early-stage VIP152 cancer study

Independent Director has left the company

Vincerx Pharma, Inc. Announces Management Appointments

Vincerx Pharma, Inc., Annual General Meeting, May 13, 2021

Vincerx, Inc. Announces Executive Changes

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven